Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine

Vaccine. 2007 Mar 22;25(13):2451-7. doi: 10.1016/j.vaccine.2006.09.019. Epub 2006 Sep 20.

Abstract

The long-term immunogenicity and vaccine efficacy (VE) of a 9-valent conjugate pneumococcal vaccine was studied in HIV infected and HIV non-infected children. VE against vaccine-serotype invasive pneumococcal disease following 6.16 years of follow-up persisted in HIV non-infected children (77.8%; 95% CI 34.4-92.5 compared to 83% after 2.3 years of follow-up), and declined from 65% to 38.8% (95% CI -7.8 to 65.2) in HIV infected children. HIV non-infected vaccinees had equal (serotypes 4, 6B, 14, 19F) or greater (serotypes 9V, 18C, 23F) proportions of serotype-specific antibody concentrations of > or =0.2microg/ml to vaccine-serotypes analyzed compared to HIV infected vaccinees at 5.3 years of age.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibody Formation
  • Child
  • Child, Preschool
  • Double-Blind Method
  • Female
  • HIV / immunology*
  • HIV Infections / immunology*
  • Humans
  • Immunization, Secondary*
  • Infant
  • Male
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Infections / virology
  • Pneumococcal Vaccines / immunology*
  • Pneumococcal Vaccines / therapeutic use
  • Streptococcus pneumoniae / immunology*
  • Treatment Outcome
  • Vaccines, Conjugate / immunology
  • Vaccines, Conjugate / therapeutic use

Substances

  • Pneumococcal Vaccines
  • Vaccines, Conjugate